Finnish Hospital Orders Nexstim NBS System 5
08 Mayo 2024 - 1:00AM
Finnish Hospital Orders Nexstim NBS System 5
Press release, Helsinki, 8 May 2024 at 9 AM
(EEST)
Finnish Hospital Orders Nexstim NBS
System 5
Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company")
has received an order for an NBS System 5 from a hospital in
Finland. This is a new customer to Nexstim.
The Nexstim Navigated Brain Stimulation (NBS)
System 5 is indicated for non-invasive mapping of the primary motor
cortex of the brain to its cortical gyrus. The system provides
information that may be used in the assessment of the primary motor
cortex for pre-procedural planning. This specific NBS system also
includes the software of an NBT® system, allowing the system to
also be used for the treatment of major depression and chronic
neuropathic pain.
Mikko Karvinen, CEO of Nexstim, comments: “Happy
to announce the expansion of our already extensive Finnish customer
base. We actively engage with the professional communities that are
relevant to Nexstim and it is great that more and more patients in
Finland can be helped with our technology.”
Further information is available on the
website www.nexstim.com, or by
contacting:
Mikko Karvinen, CEO +358 50 326
4101 mikko.karvinen@nexstim.com
About Nexstim Plc
Nexstim is a Finnish, globally operating
growth-oriented medical technology company. Our mission is to
enable personalized and effective diagnostics and therapies for
challenging brain diseases and disorders.
Nexstim has developed a world-leading
non-invasive brain stimulation technology for navigated
transcranial magnetic stimulation (nTMS) with highly sophisticated
3D navigation providing accurate and personalized targeting of the
TMS to the specific area of the brain.
Nexstim’s Diagnostics Business focuses on
commercialization of the Navigated Brain Stimulation (NBS) system.
The NBS System 5 is the only FDA cleared and CE marked navigated
TMS system for presurgical mapping of the speech and motor cortices
of the brain.
Nexstim’s Therapy Business markets and sells the
NBS System 6 which is FDA cleared for marketing and commercial
distribution for the treatment of major depressive disorder (MDD)
in the United States. In Europe, the NBS 6 system is CE marked for
the treatment of major depression and chronic neuropathic pain.
Nexstim shares are listed on Nasdaq First North
Growth Market Finland.
For more information, please visit
www.nexstim.com
- Nexstim Plc_Press release_Fin order_08052024_FINAL